About Compassionate Use to Investigational Products

Enrolling in clinical trials is the primary way for patients to access investigational drugs and biologics (investigational products) sponsored by ImmunityBio, Inc. (ImmunityBio) and all subsidiaries of ImmunityBio. A complete listing of clinical trials by all sponsors, including ImmunityBio, can be found at clinicaltrials.gov. However, physicians treating patients who are facing serious or immediately life-threating diseases or conditions and do not qualify for ongoing clinical trials may request Compassionate Use to investigational products from ImmunityBio via the following options:

• Single Patient Investigational New Drug (SPIND) – May be available to a single patient if the patient’s physician determines that there is no comparable or satisfactory alternative therapy to treat the disease or condition. In addition, the potential patient benefit should justify the potential risks of the treatment which should not be unreasonable in the context of the disease or condition to be treated.

Patients who are seeking access to ImmunityBio’s investigational products should speak with their physicians and discuss whether Compassionate Use access may be of benefit to them. If the treating physician feels that Compassionate Use access may be of benefit to the patient, the physician should contact ImmunityBio at SPIND@Immunitybio.com to make the request on behalf of their patient. Receipt of a request will be acknowledged within 3 business days.

ImmunityBio will consider Compassionate Use access requests from treating physicians in a fair, unbiased manner. Review of a Compassionate Use access request for an ImmunityBio investigational product for a serious disease or condition will be assessed using the following criteria:

• The patient or patients to be treated have a serious or immediately life-threatening disease or condition.
• The patient and a licensed physician are both willing to participate.
• The patient’s physician determines that there are no adequate alternative therapies or clinical trials available.
• There is sufficient preliminary efficacy and safety data available to support the use in the particular circumstance.
• There is sufficient evidence that the patient may expect a clinically meaningful benefit.
• Adequate supply exists to support both the ongoing clinical trials and approved compassionate use.
• The patient is not eligible or a candidate for an ImmunityBio-sponsored study. Geographic limitations to participation in a trial would typically mean a patient is not eligible.
• Compassionate Use access will not adversely impact the clinical development program – in particular the initiation, conduct, or completion of clinical investigations to support marketing approval.
• The request is made by the patient’s treating physician, unsolicited by any other individual or organization.
• The patient does not have an underlying medical condition that poses an exceptional safety risk.
• The treating physician agrees to comply with local and federal regulations and guidance’s, as well as ImmunityBio conditions.
• Additional criteria regarding the patient, the investigational product, the clinical development program, or other factors may be evaluated as relevant.

Investigational products are not approved by the FDA. There is absolutely no guarantee of access to investigational products and ImmunityBio, Inc. reserves the right to change or update the policy at any time in our sole discretion.